Bipolar Androgen Therapy + Carboplatin in mCRPC

• Status: Recruiting
• Trial end date: 2022-12-30

Summary

The purpose of this study is to determine the efficacy of BAT and carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).

• Phase: Phase 2

Details

• Lead Sponsor: St Vincent's Hospital, Sydney
• Treatments: Androgens; Carboplatin; Methyltestosterone; Pharmaceutical Solutions; Testosterone; Testosterone 17 beta-cypionate; Testosterone enanthate; Testosterone undecanoate